Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VRNG News! Up in Pre-Market- New Lawsuit
Vringo Goes After Chinese Telecom Giant ZTE Corporation for IP License Payments
Earlier today Vringo (VRNG) filed an 8-k with the SEC challenging ZTE to license patents for technology ZTE has been using since 2002. The patents cover Vringo`s proprietary technologies that are considered essential to infrastructure equipment and mobile stations compliant with GSM and GPRS specifications. In the SEC filing Vringo further states that if ZTE does not pay for the right to use its patents, Vringo will pursue all legal remedies available.
ZTE reported making over $11 Billion US dollars (RBM 93 Billion) from its infrastructure and handset business in 2011 alone.
Despite having declared it own patents to international standards for others to license, ZTE has ignored paying for licenses to patented technology it uses in its own products.
In January this year ZTE settled with Ericsson for $676 million and an ongoing license with undisclosed amounts going forward.
Vringo has over 500 patents and patent applications which were acquired from Lycos, Inc. and Nokia (NOK), and developed internally.
In August, Vringo acquired a portfolio of patents for nokia that cover cellular infrastructure, including communication management, data and signal transmission mobility management, radio resource managment and services.
Some of the acquired patents have been declared essential by Nokia to wireless communications standards such as 3G and 4G and related technologies and included GSM and WCDMA
Given that U.S. courts have clearly been kind to American companies whose patents have been infringed by foreign firms, with Apple (AAPL) being awarded over $1 billion in a settlement against Samsung (SSNLF), Vringo seems to have some leverage over ZTE to pay up, or have the battle in court.
BMPI starting to move big!
Stock just got a
$4 price target with a BUY
BMPI movin' and more coming $4 PT
http://finance.yahoo.com/news/acceleron-reiterates-buy-billmyparents-inc-110501023.html
BUY and $4 Price target for BMPI
New analyst recommendation report issued:
http://finance.yahoo.com/news/acceleron-reiterates-buy-billmyparents-inc-110501023.html
This is a $.70 stock! Gonna rock!
$BMPI gets $4 price target!
http://finance.yahoo.com/news/acceleron-reiterates-buy-billmyparents-inc-110501023.html
Looks like Scott Mattusow was right. These guys are about to sign a big celebrity to endorse their card.
Looks like your BMPI pick just got news. Nice call!
This is about to fly. Check out this report:
http://finance.yahoo.com/news/why-accumulating-trading-shares-medgenics-104702741.html
MDGN about to pop. See news:
http://finance.yahoo.com/news/why-accumulating-trading-shares-medgenics-104702741.html
BMPI breaking out with $3.30 price target.
Cup and handle forming.. About to break out!
Analysts like this penny stock. Say it is going to uplist.
http://stockcharts.com/h-sc/ui?s=BMPI&p=D&b=5&g=0&id=p08526847304
BMPI breaking out with $3.30 price target.
Cup and handle forming.. About to break out!
Analysts like this penny stock... Say it is going to uplist by next month.
http://stockcharts.com/h-sc/ui?s=BMPI&p=D&b=5&g=0&id=p08526847304
BCLI starting to move on news report!
http://finance.yahoo.com/news/upcoming-key-clinical-data-catalyst-174201443.html
BCLI starting to move on report!
http://finance.yahoo.com/news/upcoming-key-clinical-data-catalyst-174201443.html
MDGN News-- big move coming again!
This was alerted to premium subscribers at this site...
http://www.biomedreports.com/2012062998691/dont-sleep-on-this.html
Don't Sleep On This
Friday, 29 June 2012
This information is being posted for our premium subscribers first.
Despite a terrible day for the general markets on Thursday, shares of Medgenics Inc. (AMEX:MDGN) closed strong at $11.00 +1.01, +10.11% on rumors of a coming news event. The stock reached and then surpassed its previous 52-week high of $10.60. The stock also traded on +1006.24 % its average volume. Seeing a 12.1% price spike and finishing the day with a volume of 648,690.
The low-float biotech was one of our biggest winners last week after the firm announced that it had received Orphan Drug Designation from FDA for their INFRADURE Biopump (a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue) to Treat Hepatitis D.
Immediately, analysts weighed in, stating that the development had transformed the firm into a buy-out candidate given the Hepatitis space related acquisition activity; including Gilead Sciences (GILD) paying $11 billion in cash for Pharmasset and Bristol-Myers Squibb (BMY) snagging Inhibitex for $2.5 billion in cash. Other key players in the space, including Idenix Pharmaceuticals (IDIX), Achillion Pharmaceuticals (ACHN), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX) and Merck & Co. (MRK), have seen shares increase in value given that hepatitis viruses, grouped as A, B, C, and D, are considered a worldwide epidemic and highly contagious.
Still, during our own interview with Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics he indicated his team was focused on making sure that his firm will continue to build its pipeline (of multiple +billion dollar market indications for the technology) and add value beyond its current market cap. He stated cleary that: "This is now the second approval that we`ve gotten for our technology, for our company and we think it will give a lot more confidence to would-be partners and institutional investors who may have been looking for a clear sign from a regulatory agency that we have a straight shot for an approvable product within a reasonable time."
Word on the street is that the event "Will signal to the markets Medgenics' commitment to the partnering gameplan" and add even more credibility to the firm as a player which is ready to position themselves more securely in the pharma partnering space."
There is a small short interest (over 55K shares short) in the stock and some positive news early next week could put pressure on those shorts to cover. As we've seen, given the lack of available shares in the float, the stock could see another pop shortly.
Smart money remains bullish on MDGN given its path to fast regulatory approval for treating a incurable condition in a huge medical market, not to mention progress with its Biopump therapy in anemia, multiple sclerosis, arthritis, hemophilia, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases.
MDGN big move coming again!
This was alerted to premium subscribers at this site...
http://www.biomedreports.com/2012062998691/dont-sleep-on-this.html
Don't Sleep On This
Friday, 29 June 2012
This information is being posted for our premium subscribers first.
Despite a terrible day for the general markets on Thursday, shares of Medgenics Inc. (AMEX:MDGN) closed strong at $11.00 +1.01, +10.11% on rumors of a coming news event. The stock reached and then surpassed its previous 52-week high of $10.60. The stock also traded on +1006.24 % its average volume. Seeing a 12.1% price spike and finishing the day with a volume of 648,690.
The low-float biotech was one of our biggest winners last week after the firm announced that it had received Orphan Drug Designation from FDA for their INFRADURE Biopump (a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue) to Treat Hepatitis D.
Immediately, analysts weighed in, stating that the development had transformed the firm into a buy-out candidate given the Hepatitis space related acquisition activity; including Gilead Sciences (GILD) paying $11 billion in cash for Pharmasset and Bristol-Myers Squibb (BMY) snagging Inhibitex for $2.5 billion in cash. Other key players in the space, including Idenix Pharmaceuticals (IDIX), Achillion Pharmaceuticals (ACHN), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX) and Merck & Co. (MRK), have seen shares increase in value given that hepatitis viruses, grouped as A, B, C, and D, are considered a worldwide epidemic and highly contagious.
Still, during our own interview with Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics he indicated his team was focused on making sure that his firm will continue to build its pipeline (of multiple +billion dollar market indications for the technology) and add value beyond its current market cap. He stated cleary that: "This is now the second approval that we`ve gotten for our technology, for our company and we think it will give a lot more confidence to would-be partners and institutional investors who may have been looking for a clear sign from a regulatory agency that we have a straight shot for an approvable product within a reasonable time."
Word on the street is that the event "Will signal to the markets Medgenics' commitment to the partnering gameplan" and add even more credibility to the firm as a player which is ready to position themselves more securely in the pharma partnering space."
There is a small short interest (over 55K shares short) in the stock and some positive news early next week could put pressure on those shorts to cover. As we've seen, given the lack of available shares in the float, the stock could see another pop shortly.
Smart money remains bullish on MDGN given its path to fast regulatory approval for treating a incurable condition in a huge medical market, not to mention progress with its Biopump therapy in anemia, multiple sclerosis, arthritis, hemophilia, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases.
LPTN BREAKOUT -- A Video Chart
LPTN BREAKOUT Video Chart
News: Lpath Shares Breaking Out
http://finance.yahoo.com/news/lpath-shares-breaking-investors-seize-145002847.html
$8 price target on these shares.
LPTN is starting to break out- up 10% and climbing!
Sory here: http://finance.yahoo.com/news/equity-briefing-speculators-buying-lpath-174502571.html
Speculators buying Lpath, Inc. in anticipation of key catalysts
Shares of Lpath, Inc (LPTN) are trading at four times the daily average as speculators are taking positions in the firm ahead of pending catalaysts.
In January 2012, the San Diego based firm temporarily suspended dosing patients in two Phase II clinical trials looking at the use of bioactive lipids as a novel therapeutic mechanism to improve wet-AMD and Pigmented Epithelial Detachment. Lpath`s unique technology platform, the ImmuneY2(TM) approach caught the attention of Pfizer (PFE). As partners in the trial, both firms are targeting the wet AMD and a related complication called Pigmented Epithelial Detachment market, which is slated to undergo rapid expansion due to the aging demographics of the U.S. population.
The drug candidate, iSONEP(TM), had been well tolerated by all patients and had shown signs of efficacy during a Phase 1 trial,but investors were caught by surprise when the FDA determined that the a third-party fill-and-finish contractor, Formatech, Inc., was not in compliance with FDA`s current Good Manufacturing Practice ("cGMP") requirements during a period in which iSONEP(TM) clinical vials were filled.
Since then, the company has manufactured the additional drug substance required to complete the trials, and are nearing completion of the fill/finish process with an alternate contractor. The firm is reportedly preparing to resume dosing patients.
Pfizer, which continues to support the drug candidate development, took particular interest in iSONEP(TM), not only because it attenuates the permeability of the retina, but because it also blocks inflammation and fibrosis; potentially enabling the treatment to impact parameters that currently available drugs cannot ameliorate.
Some cost increases related to manufacturing additional the clinical drug supply and the cost of activities required to restart the clinical trials had prompted Pfizer to request that Lpath consider potential alternatives, including the possibility of rolling in additional clinical examinations under the key studies. No formal have been announced publicly, but if the alternative approach is taken, Lpath would recommence only the larger wet-AMD trial and would deprioritize the Pigmented Epithelial Detachment trial pending additional funding.
Lpath`s wet-AMD drug could be priced extremely highly in a market where the current standard-of-care agent, Lucentis®, is priced at $1,950 per monthly injection. Post-approval, peak sales of iSONEP(TM) could reach roughly $3.6b, according to Morgan Joseph analyst Raghuram Selvaraju, Ph.D.
For now, Pfizer has the right to exercise its option for exclusive worldwide rights to iSONEP(TM). If Pfizer exercises its option, LPath will receive an option fee as well as potential development, regulatory and commercial milestone payments. In addition, if iSONEP eventually becomes a commercial product, LPath will be entitled to receive double-digit royalties, tiered based on annual sales of iSONEP(TM).
Industry observers believe Pfizer may simply acquire Lpath (whose market cap is currently trading at just under $50 million) if pending clinical trials continue to show that the bioactive lipids approach is a legitimate option for creating a further pipeline of monoclonal antibody-based drug candidates. Said technology could offer additional therapeutic options and in some cases, better treatments for diseases in multi-billion dollar markets.
Already as part of the Pfizer Agreement, LPath has also granted to Pfizer a time-limited right of first refusal for a different drug candidate, ASONEP(TM), another formulation of the same S1P-targeted antibody which is slated for several anticipated Phase II trials. LPath successfully completed a Phase 1 clinical trial for ASONEP(TM) in 2010, and scientists believe that it holds promise for the treatment of Cancer, Multiple Sclerosis, Colitis and other diseases.
LPTN breaking out- up 7% and climbing
Sory here: http://finance.yahoo.com/news/equity-briefing-speculators-buying-lpath-174502571.html
Speculators buying Lpath, Inc. in anticipation of key catalysts
Shares of Lpath, Inc (LPTN) are trading at four times the daily average as speculators are taking positions in the firm ahead of pending catalaysts.
In January 2012, the San Diego based firm temporarily suspended dosing patients in two Phase II clinical trials looking at the use of bioactive lipids as a novel therapeutic mechanism to improve wet-AMD and Pigmented Epithelial Detachment. Lpath`s unique technology platform, the ImmuneY2(TM) approach caught the attention of Pfizer (PFE). As partners in the trial, both firms are targeting the wet AMD and a related complication called Pigmented Epithelial Detachment market, which is slated to undergo rapid expansion due to the aging demographics of the U.S. population.
The drug candidate, iSONEP(TM), had been well tolerated by all patients and had shown signs of efficacy during a Phase 1 trial,but investors were caught by surprise when the FDA determined that the a third-party fill-and-finish contractor, Formatech, Inc., was not in compliance with FDA`s current Good Manufacturing Practice ("cGMP") requirements during a period in which iSONEP(TM) clinical vials were filled.
Since then, the company has manufactured the additional drug substance required to complete the trials, and are nearing completion of the fill/finish process with an alternate contractor. The firm is reportedly preparing to resume dosing patients.
Pfizer, which continues to support the drug candidate development, took particular interest in iSONEP(TM), not only because it attenuates the permeability of the retina, but because it also blocks inflammation and fibrosis; potentially enabling the treatment to impact parameters that currently available drugs cannot ameliorate.
Some cost increases related to manufacturing additional the clinical drug supply and the cost of activities required to restart the clinical trials had prompted Pfizer to request that Lpath consider potential alternatives, including the possibility of rolling in additional clinical examinations under the key studies. No formal have been announced publicly, but if the alternative approach is taken, Lpath would recommence only the larger wet-AMD trial and would deprioritize the Pigmented Epithelial Detachment trial pending additional funding.
Lpath`s wet-AMD drug could be priced extremely highly in a market where the current standard-of-care agent, Lucentis®, is priced at $1,950 per monthly injection. Post-approval, peak sales of iSONEP(TM) could reach roughly $3.6b, according to Morgan Joseph analyst Raghuram Selvaraju, Ph.D.
For now, Pfizer has the right to exercise its option for exclusive worldwide rights to iSONEP(TM). If Pfizer exercises its option, LPath will receive an option fee as well as potential development, regulatory and commercial milestone payments. In addition, if iSONEP eventually becomes a commercial product, LPath will be entitled to receive double-digit royalties, tiered based on annual sales of iSONEP(TM).
Industry observers believe Pfizer may simply acquire Lpath (whose market cap is currently trading at just under $50 million) if pending clinical trials continue to show that the bioactive lipids approach is a legitimate option for creating a further pipeline of monoclonal antibody-based drug candidates. Said technology could offer additional therapeutic options and in some cases, better treatments for diseases in multi-billion dollar markets.
Already as part of the Pfizer Agreement, LPath has also granted to Pfizer a time-limited right of first refusal for a different drug candidate, ASONEP(TM), another formulation of the same S1P-targeted antibody which is slated for several anticipated Phase II trials. LPath successfully completed a Phase 1 clinical trial for ASONEP(TM) in 2010, and scientists believe that it holds promise for the treatment of Cancer, Multiple Sclerosis, Colitis and other diseases.
Easy Double from here -- LPTN
News just hit the wires that supports the video below:
LPTN NEWS! - Possible Pfizer Buyout Mentioned
http://finance.yahoo.com/news/equity-briefing-speculators-buying-lpath-174502571.html
Agreed... And there are people starting to notice.
Regenicin soars but may head even higher post FDA orphan product status approval
Click This Link To Read The Report
Bottom bouncer starting to break out again!
Headed back to $.60 as technical analysis shows: CVM
Nice Technical Alert: CVM
Big Board Listed Phase III Drug Company looks like prices are headed back to $.60 again
Check out the video for a great technical analysis
Break out for OMPI on $20 Buy Out Chatter
OMPI breaking out on buy-out rumors
Breakout chart and info for Neptune:
http://chart.ly/hkov5al
NEPT: Breakout Watch (video)
This stock has been on the move and was just issued a BUY recommendation with a $9 target and earnings are due out soon. If it breakout out today, it could be headed much higher.
[ty]X6_Z8pmI9UY[/yt]
Also more here:
Full chart here: http://chart.ly/hkov5al
VIDEO BREAKOUT CHART: NEPT
This stock was just issued a $9 price target and is starting to break-out
Looks like $NEPT has started to break out!
http://seekingalpha.com/article/510771-2-big-board-biotech-breakout-candidates-with-reasons-to-run?source=yahoo
NEPT starting to break out!
This one is headed much higher on pending news and milestones. Cehck out all the positive attention they have been getting:
http://finance.yahoo.com/q?s=NEPT&x=30&y=13
Technical analysis chart here:
NEPT starting to break out!
This one is headed much higher on pending news and milestones. Cehck out all the positive attention they have been getting:
http://finance.yahoo.com/q?s=NEPT&x=30&y=13
Duh! Check the stock chart and see for yourself. Then ask yourself. Was GLTC a break out...or not?
GLTC Breakout Video Chart
Video Chart for Breakout Candidate *GLTC*
Cel-Sci's chart indicates stock may be getting ready for the next leg up
Complete story with charts...
http://www.smallcapnetwork.com/Cel-Scis-chart-indicates-stock-may-be-getting-ready-for-the-next-leg-up/s/via/10011/article/view/p/mid/1/id/3/
Cel-Sci's chart indicates stock may be getting ready for the next leg up
Complete story with charts...
http://www.smallcapnetwork.com/Cel-Scis-chart-indicates-stock-may-be-getting-ready-for-the-next-leg-up/s/via/10011/article/view/p/mid/1/id/3/